TPI-287 is what makes this one interesting. The milestone/royalty rights are not in question as an asset of the estate. The contingency is whether Archer can find continued success. The link above is to the various trials of TPI-287. They have several at MD Anderson...likewise if you google TPI-287 under the scholar and video and blog categories, one can find a large amount of due diligence on the compounds prospects. Ultimately, it's a levered bet on the compound.
But you probably know a lot more about bk than me. Good luck.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.